JAZZ PHARMACEUTICALS UK LIMITED
Get an alert when JAZZ PHARMACEUTICALS UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-20 (in 5mo)
Last made up 2025-10-06
Watchouts
None on the register
Cash
£0
+100% vs 2023
Net assets
£40M
+63.5% vs 2023
Employees
194
+9.6% vs 2023
Profit before tax
£11M
+115.9% vs 2023
Name history
Renamed 3 times since incorporation
- JAZZ PHARMACEUTICALS UK LIMITED 2016-04-09 → present
- EUSA PHARMA (EUROPE) LIMITED 2006-08-18 → 2016-04-09
- TALISKER PHARMA LIMITED 2002-12-17 → 2006-08-18
- MINMAR (625) LIMITED 2002-10-07 → 2002-12-17
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £89,108,306 | £108,131,474 | |
| Operating profit | £5,400,314 | £10,739,075 | |
| Profit before tax | £5,318,402 | £11,481,127 | |
| Net profit | £4,602,716 | £11,759,017 | |
| Cash | -£1,211 | £0 | |
| Total assets less current liabilities | £25,167,700 | £40,711,593 | |
| Net assets | £24,298,062 | £39,731,135 | |
| Equity | £24,298,062 | £39,731,135 | |
| Average employees | 177 | 194 | |
| Wages | £24,015,637 | £29,711,107 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 6.1% | 9.9% | |
| Net margin | 5.2% | 10.9% | |
| Return on capital employed | 21.5% | 26.4% | |
| Current ratio | 1.69x | 2.85x | |
| Interest cover | 22.90x | 164.81x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic.”
Significant events
- “Effective 1 April 2024, the Company entered into a Business Transfer Agreement to acquire the business and assets of GW UK Services Limited, a sister concern and part of the Jazz group. As part of this transaction, employees previously employed by GW UK Services Limited were transferred to Jazz Pharmaceuticals UK Limited.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 21 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PATEL, Alkesh | Secretary | 2024-04-03 | — | — |
| FLANAGAN, Amanda | Director | 2024-10-01 | Aug 1971 | Irish |
| SPACKMAN, David James | Director | 2025-02-07 | Jan 1976 | British |
Show 21 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DOODY, Aislinn Jane, Ms. | Secretary | 2013-05-10 | 2024-04-03 |
| EVANS, Zoe | Secretary | 2006-10-16 | 2012-09-28 |
| OLDRIDGE, Kerry Jane | Secretary | 2012-09-28 | 2013-05-10 |
| CLYDE SECRETARIES LIMITED | Corporate Secretary | 2002-10-07 | 2006-07-07 |
| REED SMITH CORPORATE SERVICES LIMITED | Corporate Secretary | 2006-07-07 | 2006-10-16 |
| COOK, David John | Director | 2007-01-03 | 2013-01-31 |
| CORN, Timothy Henry, Dr | Director | 2007-01-03 | 2012-09-28 |
| DAGHER, Joseph | Director | 2019-06-28 | 2020-12-09 |
| DUFFY, Christopher William | Nominee Director | 2002-10-07 | 2003-09-29 |
| EVANS, Zoe | Director | 2007-01-03 | 2012-09-28 |
| KIELY, Hugh | Director | 2012-09-28 | 2021-11-02 |
| LEPELLETIER, Nelly | Director | 2021-11-02 | 2025-02-07 |
| MCGILL, Iain Robert | Director | 2013-01-31 | 2019-06-28 |
| MORTON, Bryan Geoffrey | Director | 2006-07-07 | 2012-09-28 |
| O'BRIEN, Bridget Mary | Director | 2012-09-28 | 2021-11-02 |
| PAGE, David William | Nominee Director | 2002-10-07 | 2003-09-29 |
| PEARCE, Samantha Jane Laura | Director | 2020-12-09 | 2024-10-01 |
| PHILLIPS, James Neil, Dr | Director | 2003-09-29 | 2007-11-30 |
| PRECIOUS, John Richard | Director | 2004-09-10 | 2006-07-07 |
| RAINEY, Robert Edward Holmes | Director | 2005-06-01 | 2006-07-07 |
| VAN BEYSTERVELDT, Adrianus Maria | Director | 2007-11-30 | 2009-07-08 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Jazz Pharmaceuticals Uk Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2022-04-05 | Active |
| Jazz Pharmaceuticals Lux Sarl | Corporate entity | Shares 75–100% | 2016-04-06 | Ceased 2022-04-05 |
Filing timeline
Last 20 of 174 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-12-12 RESOLUTIONS Resolution
- 2025-12-12 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-12 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2025-12-12 | SH20 | capital | Legacy | |
| 2025-12-12 | CAP-SS | insolvency | Legacy | |
| 2025-12-12 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-12 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-11 | SH01 | capital | Capital allotment shares | |
| 2025-12-11 | SH01 | capital | Capital allotment shares | |
| 2025-10-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-09-30 | AA | accounts | Accounts with accounts type full | |
| 2025-02-10 | AP01 | officers | Appoint person director company with name date | |
| 2025-02-10 | TM01 | officers | Termination director company with name termination date | |
| 2024-10-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-04 | AA | accounts | Accounts with accounts type full | |
| 2024-10-02 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-10-01 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-04-18 | AP03 | officers | Appoint person secretary company with name date | |
| 2024-04-18 | TM02 | officers | Termination secretary company with name termination date | |
| 2023-10-16 | AA | accounts | Accounts with accounts type full | |
| 2023-10-09 | CS01 | confirmation-statement | Confirmation statement with updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 9
- Capital events
- 4
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+21.3%
£89,108,306 £108,131,474
-
Cash
+100%
-£1,211 £0
-
Net assets
+63.5%
£24,298,062 £39,731,135
-
Employees
+9.6%
177 194
-
Operating profit
+98.9%
£5,400,314 £10,739,075
-
Profit before tax
+115.9%
£5,318,402 £11,481,127
-
Wages
+23.7%
£24,015,637 £29,711,107
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers